Arc 01 · Surgery avoider
Robert M.
Told I needed a knee replacement. Six months later I'm playing golf again.
§ 004 · Dossier
Three arcs. The evidence. The people we decline.
What we can show you.
Not what we claim.
Three patient arcs, charted end-to-end. The peer-reviewed literature we actually read. And the inquiries our physicians turn away. Look at all three before you decide.
20yrs
Dr. Amescua's tenure in regenerative medicine & MSC protocols
Declined
Inquiries we turn away after physician screening
11papers
Peer-reviewed studies we cite, every one linked
§ 004.1 · Three patient arcs
Before. Treatment.
Before. Treatment.
6 months later.
Three composite patient arcs, one per persona we see most often. Each shows baseline, protocol, and measurable change at the follow-up endpoint for that case. Partial results are included, not hidden. Real named accounts coming soon.
Arc 02 · Longevity optimizer
Sarah K.
I didn't come in broken. I came in ahead of the curve. They spent half the consult telling me what they wouldn't promise.
Arc 03 · Complex case · measurable gains
James T.
The first conversation that felt honest, and the first treatment that gave me real, measurable ground back.
§ 004.1.1 · More patient accounts
These three arcs are a sample. Browse the full library by track.
§ Note on names Patient names above are pseudonyms. Details reflect patterns we see most often; identified patient accounts with written consent will replace these as the Patient Stories library comes online.
§ 004.2 · The filter
Inquiries declined after physician screening.
A clinic that accepts every inquiry is optimizing for throughput, not outcomes. We'd rather turn a patient away than take a deposit against a treatment that probably won't change their life.
- 01Structural severity past the realistic ceiling. End-stage collapse, complete ligamentous failure. Surgery is the better conversation.
- 02Expectation mismatch we can't reconcile. A patient who cannot hear the honest version of what this treatment does and doesn't do.
- 03Active medical contraindications. Ongoing malignancy in specific staging, uncontrolled autoimmune activity. Safety, not policy.
Regulatory
COFEPRIS authorized
Cell therapies regulated under Mexico's federal health authority.
Facility
Hospital Angeles Tijuana
JCI-accredited private hospital. Treatment in-suite, not a roadside clinic.
Laboratory
GMP-compliant
Cell product manufactured with full chain-of-custody, lot-traceable to release.
Physician review
Every case
Consult is a clinical assessment, not a sales call. No coordinator layer.
§ 004.3 · Evidence
Eleven papers. Every one linked.
The peer-reviewed literature our physicians actually read, rated on evidence strength, annotated with where each falls short. Full reading list lives on the Learn page.
Well-supported
Promising
Early / narrow
-
Well-supported
Knee OA · Meta-analysis
MSC in knee osteoarthritis: systematic review of 8 RCTs
Cui et al. · J Orthop Surg Res · 2025 · n=502 · WOMAC improvement sustained at 6 & 12 months.
-
Well-supported
IV · Safety meta-analysis
Intravascular MSC: pooled safety data
Thompson et al. · EClinicalMedicine · 2020 · dozens of trials pooled · no significant SAE association.
-
Well-supported
GvHD · Phase III
MSC-FFM for steroid-refractory acute GvHD
Bader et al. · Bone Marrow Transplant · 2018 · n=69 · 83% day-28 response. Safety base for the field.
-
Well-supported
IV · ARDS RCT
UC-MSC for COVID-19 ARDS: randomized trial
Lanzoni et al. · Stem Cells Transl Med · 2021 · survival 91% vs 42% · strong IV anti-inflammatory signal.
-
Promising
Knee · UC-MSC dosing
UC-MSC repeated dosing vs HA for knee OA
Matas et al. · Stem Cells Transl Med · 2019 · repeated allogeneic outperformed single-dose and HA at 12 mo.
-
Promising
Shoulder · 36-mo follow-up
Adipose MSC for glenohumeral OA, 3-year data
Natali et al. · J Clin Med · 2023 · among longest follow-up datasets for shoulder-OA cell therapy.
-
Promising
Mechanism · Review
MSC-derived exosomes for cell-free therapy
Phinney & Pittenger · Stem Cells · 2017 · foundational: MSC effects are paracrine, not engraftment.
-
Early / narrow
Neuro · Phase I
Intrathecal MSC-NP in progressive MS, 2-yr
Harris et al. · Neurol Neuroimmunol Neuroinflamm · 2021 · n=20 · sustained EDSS in a subset. Narrow use only.
-
Early / narrow
Honest limits · Commentary
MSCs: clinical challenges & opportunities
Galipeau & Sensébé · Cell Stem Cell · 2018 · skeptical from the inside. We agree with most of it.
-
Early / narrow
Vetting · Field survey
Selling stem cells in the USA: DTC clinic audit
Turner & Knoepfler · Cell Stem Cell · 2016 · 570+ U.S. businesses · how to tell a real clinic from a bad one.
-
Early / narrow
Regulatory · Review
Global regulatory review for cell therapies
Salmikangas et al. · Molecular Therapy · 2019 · FDA vs EMA vs others · context for "Why Tijuana."
§ 004.4 · Who reviews the data
The people standing behind what's on this page.
Every patient arc, every paper on the evidence grid, and every decline decision passes through these three.
Medical Director
Dr. Cesar Amescua, MD
MD, UNAM · 20+ years in regenerative medicine & tissue engineering.
Physician, Regenerative Medicine
Dr. Rocio Ambrosio Nuño, MD
MD, UABC · Anesthesiology residency, UAS. Interventional procedures & in-suite safety.
Regenerative Research Consultant
Dr. Alejandro Castillo, MD
Biomedical research. Reads the literature and pushes back when the case outruns the evidence.
§ 004.5 · Your case, not ours
Proof is general.
Proof is general.
A consult is yours.
This page is what we can show everyone. A consult is a physician reading your case, your imaging, and your honest question. No commitment. No pressure.
Book a consult →Not medical advice. Individual results vary. All patients undergo physician screening before any treatment is recommended. Cell therapies at Celva Bio are regulated by COFEPRIS in Mexico; most are not FDA-approved products in the United States.